A 50 y/o male with a PMH significant for HIV/HCV co-infection, and chronic renal insufficiency, presented to the ED with a one week history of progressive dyspnea and diffuse abdominal discomfort. He reported resting shortness of breath without orthopnea, PND, or chest pain. His abdominal pain was diffuse, and he denied nausea, vomiting, increased abdominal girth or lower extremity edema.
He was diagnosed with HIV 3 months earlier, following an admission for septic arthritis. One month ago his CD4+ count was 125 and his viral load 200,000 copies, at which time he began antiretroviral therapy with Combivir (zidovudine/lamivudine) and Sustiva (efavirez) and prophylactic therapy with Bactrim. The patient reported strict compliance with his medical regimen.
On admission his vitals were as follows: temperature 98.9 F, pulse 107 bpm, blood pressure 112/63, respirations 28/min with an oxygen saturation of 96% on room air. The physical exam revealed a thin black male in moderate discomfort, exhibiting Kussmaul breathing with an otherwise clear lung exam. Abdominal exam revealed normal bowel sounds and mild diffuse tenderness, without rebound or guarding. There was no evidence of JVD, lower extremity edema, or S3.
Laboratory data revealed: sodium 136, potassium 5.6, chloride 112, bicarbonate 11, BUN 36, creatinine 2.6, glucose 113; WBC 6.4, hemoglobin 9.1, and platelets 193; AST 306, ALT 77, alkaline phosphatase 567, albumin 2.4. Arterial blood gas values were pH 7.33, pCO2 22, PO2 154. Finally, chest x-ray demonstrated clear lungs and EKG revealed normal sinus rhythm with T wave inversions in V1-V6.
Discussion
Of The Acid-Base Disorder -A "Normal Gap" Lactic Acidosis? Initial review of the arterial blood gas and chemistry panel revealed a metabolic acidosis with an expected respiratory compensation (calculated PCO2 by Winter's formula = 24+/-2). The calculated anion gap was 13, leading us to conclude that the primary disorder was a non-gap acidosis. However, prior lab studies were available for this patient, which revealed a baseline bicarbonate of 20 (presumably related to chronic renal insufficiency) and anion gap of 5 (presumably related to hypoalbuminemia). The presence of a delta anion gap of 8 suggested a true anion gap acidosis. A serum lactate was subsequently measured, which was markedly elevated at 68.6.
Diagnosis And Clinical Outcome
The patient was admitted with the diagnosis of lactic acidosis, likely secondary to his nucleoside reverse transcriptase inhibitor (NRTI) therapy with Combivir. AST/ALT values peaked at 3621/721 respectively the morning after admission. By withholding antiretroviral therapy, the lactic acid level trended back to normal values and the patient's transaminases returned to his baseline. He continued to improve symptomatically within about 1 week and had returned to his baseline functional status.
Discussion on NRTIs and Lactic Acidosis
The development of lactic acidosis is a very rare, but often fatal, complication of therapy with nucleoside analogues. The estimated incidence of this disorder is only about 1-4 cases per 1000 person years; however it carries a sobering mortality rate of about 50% 1. Though an exact mechanism is yet to be clearly defined, it appears to be related to the inhibition of mitochondrial DNA polymerase and development of hepatic steatosis.
Perhaps of larger interest to clinicians is the ability to identify important risk factors for the development of lactic acidosis. Due to the rarity of this disorder, large-scale studies are difficult to design to evaluate this question. However, a series of case reports and cohort studies have been published. Treatment with any of the NRTIs has been associated with lactic acidosis; however the use of stavudine and lamivudine appears to confer the greatest risk 2,3. Another small cohort study suggests additional risk factors may include creatinine clearance of <70 mL/min and a nadir CD4+count of <200 cells/m3. 4 Finally, pregnancy has also been targeted as a potential risk factor 5-7.
In conclusion, the development of lactic acidosis during therapy with NRTIs is a rare but potentially lethal complication. Thus, clinicians should maintain a high level of clinical suspicion when HIV+ patients on such therapy complain of GI distress, dyspnea or general malaise, particulary in the setting of 
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A Man with Dyspnea and Diffuse Abdominal Pain
A -Capsule Image
This is a pedunculated jejunal polyp. Because the patient is asymptomatic and the polyp is less than 15 mm in size, no therapeutic intervention is recommended at this time. Patients with PJS should be screened endoscopically with EGD, colonoscopy, and small bowel evaluation at least every two years after the age of 12.
Submitted by Carl D. Mele, MD
B -Radiograph
A 3 x 2 cm type Ia choledochal cyst is visualized at the junction of the common hepatic and common bile ducts (note the cystic duct take-off from the choledochal cyst itself ). Although the patient has minimal symptoms, the cyst needs to be surgically excised because of an increased risk of cholangitis and malignancy. This is a congenital abnormality seen more commonly in women, with an incidence of roughly 1 in 15,000.
Submitted by Carl D. Mele, MD
C -Slide
Liver biopsy of the nodules shows microabscesses with fungal elements on GMS (silver) stain. Note the extracellular beaded fungal elements embedded in debris, surrounded by fibrosed liver parenchyma.
Submitted by Jun Liu, MD
D -Slide
Skin biopsy of a discrete lesion shows a foci of multiple giant multinucleated cells within the dermis layer. This finding is characteristic of herpes simplex, which systemically disseminated in this immunocompetent patient, causing multiorgan failure. With intravenous antiviral therapy, the patient made a full recovery.
Submitted by Aparna Mukherjee, MD
E -Radiograph
The diagnosis is chylothorax, which is characterized by pleural fluid with a turbid or milky white appearance, secondary to high The procedure shown above is a thoracic duct embolization.
The effustion can be seen at the apex of the left lung.
Radiographic dye is injected into a surgically exposed lymphatic channel in the foot. After several minutes to hours, the dye migrates to the cisterna chyle and into the thoracic duct. At this point a needle is inserted into the thoracic duct and a glue-like material is injected, essentially thrombosing the entire duct.
Submitted by Bryan Pukenas, MD
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